# Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

> **NCT00807495** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Burkitt's Lymphoma
- T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma
- Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component

## Interventions

- **DRUG:** Alisertib

## Key facts

- **NCT ID:** NCT00807495
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-10
- **Primary completion:** 2011-01-04
- **Final completion:** 2013-02-13
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807495, "Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00807495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*